In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Carolina Säll; Lene Alifrangis; Kirsten Dahl; Martin Haljeta Friedrichsen; Sune Boris Nygård; Kim Kristensen

doi:10.1124/dmd.122.000865

OtherArticle

In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Carolina Säll, Lene Alifrangis, Kirsten Dahl, Martin Haljeta Friedrichsen, Sune Boris Nygård and Kim Kristensen

Drug Metabolism and Disposition June 9, 2022, DMD-AR-2022-000865; DOI: https://doi.org/10.1124/dmd.122.000865

Carolina Säll

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: cxls@novonordisk.com

Lene Alifrangis

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kirsten Dahl

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Haljeta Friedrichsen

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sune Boris Nygård

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim Kristensen

1Novo Nordisk A/S, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Article Information

DMD-AR-2022-000865

DOI

https://doi.org/10.1124/dmd.122.000865

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0090-9556

Online ISSN

1521-009X

History

Published online June 9, 2022.

Author Information

Carolina Säll1,*,
Lene Alifrangis1,
Kirsten Dahl1,
Martin Haljeta Friedrichsen1,
Sune Boris Nygård1, and
Kim Kristensen1

¹Novo Nordisk A/S, Denmark

↵* Corresponding Author:
Carolina Säll, Novo Nordisk A/S, Copenhagen, N/A, Denmark. E-mail: cxls{at}novonordisk.com

Statistics from Altmetric.com

Article usage

Article usage: June 2022 to June 2022

	Abstract	Full	Pdf
Jun 2022	397	24	255

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 50, Issue 6

1 Jun 2022

Table of Contents
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherArticle

In vitro CYP suppression by peptide not observed in clinic

Carolina Säll, Lene Alifrangis, Kirsten Dahl, Martin Haljeta Friedrichsen, Sune Boris Nygård and Kim Kristensen

Drug Metabolism and Disposition June 9, 2022, DMD-AR-2022-000865; DOI: https://doi.org/10.1124/dmd.122.000865

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

OtherArticle

In vitro CYP suppression by peptide not observed in clinic

Carolina Säll, Lene Alifrangis, Kirsten Dahl, Martin Haljeta Friedrichsen, Sune Boris Nygård and Kim Kristensen

Drug Metabolism and Disposition June 9, 2022, DMD-AR-2022-000865; DOI: https://doi.org/10.1124/dmd.122.000865

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Main menu

User menu

Search

In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic

Article Information

Author Information

Statistics from Altmetric.com

Article usage

Article usage: June 2022 to June 2022

In this issue

In vitro CYP suppression by peptide not observed in clinic

Citation Manager Formats

In vitro CYP suppression by peptide not observed in clinic

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals